CliffBio
small molecule

RENVELA

SEVELAMER CARBONATE

Loss of exclusivityDecember 2030latest FDA-listed patent expiry
CompanyGenzyme →See this company's full patent-cliff portfolio

Drug detail

Brand nameRENVELA
Active ingredientSEVELAMER CARBONATE
Strength800MG/PACKET
Dosage formFOR SUSPENSION
RouteORAL
ModalitySmall molecule
FDA approvalAugust 2009
Marketing statusDISCN

Listed patents

PatentExpiresType
9095509December 2030product

More from Genzyme

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.